Download PDF
Thromb Haemost 1995; 73(02): 287-290
DOI: 10.1055/s-0038-1653766
Original Article
Fibrinolysis
Schattauer GmbH Stuttgart

Desmin 370, a Low Molecular Weight Dermatan Sulfate, Reduces the Weight of Preformed Thrombi in Rats Made Afibrinogenemic by Ancrod

Miriam Barbanti
The Alfa Wassermann, Bologna, University of Bari, Italy
,
Fiorella Calanni
The Alfa Wassermann, Bologna, University of Bari, Italy
,
Egidio Marchi
The Alfa Wassermann, Bologna, University of Bari, Italy
,
Nicola Semeraro
1   The Department of Biomedical Sciences and Human Oncology, Section of General Pathology, University of Bari, Italy
The Alfa Wassermann, Bologna, University of Bari, Italy
,
Mario Colucci
1   The Department of Biomedical Sciences and Human Oncology, Section of General Pathology, University of Bari, Italy
The Alfa Wassermann, Bologna, University of Bari, Italy
› Author Affiliations
Further Information

Publication History

Received 30 August 1994

Accepted after revision 26 October 1994

Publication Date:
09 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Desmin 370 (D370), a low molecular weight dermatan sulfate, has been shown to induce a marked reduction of the weight of preformed venous thrombi in rats and rabbits by mechanisms that appeared largely independent of inhibition of thrombus accretion. In order to provide further support for such a mechanism, we exploited the defibrinating capacity of ancrod to obtain a thrombosis model characterized by the lack of thrombus growth and thus sensitive only to agents promoting thrombus lysis. Thrombus formation in anesthetized rats was induced by vena cava ligature. Injection of ancrod (5 U/kg) 5 h after induction of venous stasis caused a more than 95% reduction in plasma fibrinogen and prevented thrombus accretion as indicated by the lack of thrombus weight increase during the 3h experimental period (12.2 ° 0.6 vs 14.5 ° 1 as compared to 12.6 ° 0.6 vs 19.6 ° 0.8, p <0.01, in control rats) and by the almost complete (>90%) inhibition of125I- fibrin(ogen) binding to thrombi. Moreover, when ancrod was given 1 h before vena cava ligature, no thrombi were formed within 2 h whereas at the same time interval visible thrombi were present in all control rats. Administration of D370 (10 mg/kg) to thrombus bearing rats, 1 h after induction of afibrinogenemia, resulted in a significant reduction in thrombus weight (43% after 2h, p <0.01) which was only slightly lower than that recorded in normofibrinogenemic rats (54%). Enhancement of plasma fibrinolytic activity by ancrod had no influence on thrombus lysis and was not at all affected by administration of D370. These data provide additional and more direct evidence that D370 may promote thrombus lysis independently of inhibition of thrombus accretion.

 

  • References

  • 1 Tollefsen DM, Pestka CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 1983; 258: 6713-6716
    PubMedSearch in Google Scholar
  • 2 Mascellani G, Bianchini P. European patent 1990 0221977, USA patent 1990 4973580
    PubMed
  • 3 Barbanti M, Calanni F, Milani MR, Marchi E, Semeraro N, Colucci M. Therapeutic effect of a low molecular weight dermatan sulphate (Desmin 370) in rat venous thrombosis. Evidence for an anticoagulant independent mechanism Thromb Haemostas 1993; 69: 147-151
    PubMedSearch in Google Scholar
  • 4 Colucci M, Triggiani R, Cavallo LG, Chiumarulo P, Barbanti M, Semeraro N. Therapeutic effect of a LMW dermatan sulphate in experimental venous thrombosis. Comparison with hirudin and heparin Fibrinolysis 1992; 6 suppl (Suppl. 02) 136 (Abstr.356)
    PubMedSearch in Google Scholar
  • 5 Bell WR, Bolton G, Pitney WR. The effect of ancrod on blood coagulation factors. Br J Haematol 1968; 15: 589-602
    CrossrefPubMedSearch in Google Scholar
  • 6 Forbes CD, Barbenell J, Prentice CR M. Treatment of thrombosis by sequential therapy with ancrod followed by streptokinase. Haemostasis 1976; 5: 348-354
    PubMedSearch in Google Scholar
  • 7 Cercek B, Lew AS, Hod H, Yano J, Reddy NKN, Ganz W. Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin. Circulation 1986; 74: 583-587
    CrossrefPubMedSearch in Google Scholar
  • 8 Cercek B, Lew AS, Hod H, Yano J, Lewis B, Reddy NK N, Ganz W. Ancrod enhances the thrombolytic effect of streptokinase and urokinase. Thromb Res 1987; 47: 417-426
    CrossrefPubMedSearch in Google Scholar
  • 9 Reyers I, Mysliwiec M, Mussoni L, Donati MB. Stasis induced venous thrombosis. In: >Standardization of animal models of thrombosis. Breddin K, Zimmermann R. eds Schattauer, Stuttgart: 1983. pp 99-108
    Search in Google Scholar
  • 10 Clauss A. Rapid physiological coagulation method for the determination of fibrinogen. Acta Haematol 1957; 17: 237-239
    CrossrefPubMedSearch in Google Scholar
  • 11 Haverkate F, Brakman P. Fibrin plate assay. In: Progress in Chemical Fibrinolysis and Thrombolysis, vol 1. Davidson JF, Samama MM, Desnoyers PC. eds Raven Press; New York: 1975: pp151-159
    Search in Google Scholar
  • 12 Krishnamurti C, Barr CF, Hassett MA, Young GD, Alving BM. Plasminogen activator inhibitor: a regulator of ancrod-induced fibrin deposition in rabbits. Blood 1987; 69: 798-803
    PubMedSearch in Google Scholar
  • 13 Marsh NA. Does heparin stimulate fibrinolysis. Br J Haematol 1990; 76: 163-167
    CrossrefPubMedSearch in Google Scholar
  • 14 Weitz J, Hirsh J. New anticoagulant strategies. J Lab Clin Med 1993; 122: 364-373
    PubMedSearch in Google Scholar
  • 15 Clozel JP, Holvoet P, Tschopp T. Experimental pulmonary embolus in the rat: a new in vivo model to test thrombolytic drugs. J Cardiovasc Pharmacol 1988; 12: 520-525
    CrossrefPubMedSearch in Google Scholar
  • 16 Collen D, Stassen JM, Verstraete M. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. J Clin Invest 1983; 71: 368-376
    CrossrefPubMedSearch in Google Scholar